Does adjusted-dose prasugrel compared with clopidogrel improve ischemic events and safety in Japanese patients with Acute Coronary Syndrome?
Adjusted-dose prasugrel (20/3.75 mg) demonstrates a favorable efficacy and safety profile in Japanese patients with ACS.
Prasugrel 20/3.75 mg was associated with a low incidence of ischemic events, similar to the results of TRITON-TIMI 38, and with a low risk of clinically serious bleeding in Japanese ACS patients.
Saito et al. (Wed,) studied this question.